GlobeNewswire All Public CompaniesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:02:26·⚡ 决策 09-01 19:54:04 +51m38s·55.9 天前
Parabilis Medicines将参加摩根士丹利全球医疗会议炉边谈话
完整正文显示只是医疗会议炉边谈话日程公告，没有临床、监管、商业化、融资或财务变化；额外行情、KB或先例不会改变不交易结论。
📄 原文GlobeNewswire All Public Companies↗ 原文
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceut…
不做 Parabilis Medicines（PBLS.US）
仅为常规医疗会议参会公告，没有临床数据、监管进展、合作、融资或业绩增量，缺乏可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
本次消息的实质是Parabilis Medicines披露CEO将参加Morgan Stanley医疗会议并提供音频直播链接，属于常规IR活动通知。正文没有新增药物数据、试验读出、监管里程碑、合作授权、融资或收入指引，因此无法建立收入、利润、估值或概率重估链条；不构成方向明确的可交易事件。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 会议上未来可能披露新信息，但当前公告本身没有可交易增量，需等正式数据或管理层新表述。
先例如何影响了这次决策
对本次决策的影响:源文本已足以判定不交易，先例不会改变标的、方向或仓位。
方向:常规会议参会公告不具备明确方向，未进入外部先例量化阶段。
涨幅量级:无基本面增量，先例幅度校准不适用。
形态:未研究见光死模式，因为当前事件不是可交易催化。
原文全文
展开原文 · 2,090 字
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24
th
Annual Global Healthcare Conference in New York, NY at 2:35 PM ET on Wednesday, September 16, 2026.
The live audio webcast will be available on the Investors section of the Parabilis website at
investors.parabilismed.com
.
About Parabilis Medicines
Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and a range of other rare and common solid tumor indications. Beyond zolucatetide, Parabilis is pursuing a follow-on β-catenin degrader program and advancing additional Helicon-based programs focused on other challenging targets, including ERG and allosteric AR
ON
in prostate cancer, where we believe our medicines could have life-altering impact. For more information, visit
www.parabilismed.com
or follow us on
LinkedIn
.
Media Contact:
Jessica Freifeld
media@parabilismed.com
Investor Contact:
Tom Kotarakos
investors@parabilismed.com
th
Annual Global Healthcare Conference in New York, NY at 2:35 PM ET on Wednesday, September 16, 2026.
The live audio webcast will be available on the Investors section of the Parabilis website at
investors.parabilismed.com
.
About Parabilis Medicines
Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and a range of other rare and common solid tumor indications. Beyond zolucatetide, Parabilis is pursuing a follow-on β-catenin degrader program and advancing additional Helicon-based programs focused on other challenging targets, including ERG and allosteric AR
ON
in prostate cancer, where we believe our medicines could have life-altering impact. For more information, visit
www.parabilismed.com
or follow us on
.
Media Contact:
Jessica Freifeld
media@parabilismed.com
Investor Contact:
Tom Kotarakos
investors@parabilismed.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。